1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

COVID-19’s Damage To Gene Therapy Development May Last Years

 
• By Derrick Gingery

US FDA's Peter Marks says the field is robust, but hedges on approval predictions for the coming years because of pandemic’s effect.

Peter Marks at FDLI Regenerative Medicine conference screenshot
CBER Director Peter Marks said the pandemic also exasperated the backlog of pending INTERACT meetings. • Source: Screenshot

Gene therapy development and approval likely was slowed by the coronavirus pandemic, which could endanger projections for the explosion in the sector going forward.

In calendar year 2019, the US Food and Drug Administration received 243 IND applications for gene therapies, which was followed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.

Cell/Gene Therapy Cost Recovery Options Could Include Pre-Approval Public ‘Bridge’ Funding

 
• By Kate Rawson

Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 
• By Eliza Slawther

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.